Cash and Cash Equivalents, at Carrying Value of NovaBridge Biosciences from 31 Dec 2018 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD and CNY
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
NovaBridge Biosciences quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 31 Dec 2018 to 30 Jun 2025.
  • NovaBridge Biosciences Cash and Cash Equivalents, at Carrying Value for the quarter ending 30 Jun 2025 was $165,404,000.
NovaBridge Biosciences quarterly Cash and Cash Equivalents, at Carrying Value in CNY history and change rate from 31 Dec 2018 to 30 Jun 2025.
  • NovaBridge Biosciences Cash and Cash Equivalents, at Carrying Value for the quarter ending 31 Dec 2023 was ¥2,141,445,000, a 33% decline year-over-year.
Source SEC data
View on sec.gov
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)
Cash and Cash Equivalents, at Carrying Value, Quarterly (CNY)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

NovaBridge Biosciences Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $165,404,000 30 Jun 2025 6-K 06 Oct 2025 2025 Q2
Q4 2024 $68,263,000 -$223,243,000 -77% 31 Dec 2024 6-K 06 Oct 2025 2025 Q2
Q4 2023 $291,506,000 -$51,416,000 -15% 31 Dec 2023 20-F 03 Apr 2025 2024 FY
Q4 2022 $342,922,000 -$210,013,000 -38% 31 Dec 2022 20-F 03 Apr 2025 2024 FY
Q2 2022 $554,023,000 30 Jun 2022 6-K 10 Nov 2022 2022 Q2
Q4 2021 $552,935,000 -$176,380,000 -24% 31 Dec 2021 20-F 29 Apr 2022 2021 FY
Q4 2020 $729,315,000 +$565,927,000 +346% 31 Dec 2020 20-F 28 Apr 2021 2020 FY
Q3 2020 $435,963,000 30 Sep 2020 6-K 05 Feb 2021 2020 Q3
Q4 2019 $163,388,000 31 Dec 2019 20-F 29 Apr 2020 2019 FY

NovaBridge Biosciences Quarterly Cash and Cash Equivalents, at Carrying Value (CNY)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2023 ¥2,141,445,000 -¥1,072,560,000 -33% 31 Dec 2023 20-F 30 Apr 2024 2023 FY
Q4 2022 ¥3,214,005,000 -¥309,627,000 -8.8% 31 Dec 2022 20-F 30 Apr 2024 2023 FY
Q2 2022 ¥3,710,901,000 30 Jun 2022 6-K 10 Nov 2022 2022 Q2
Q4 2021 ¥3,523,632,000 -¥1,235,146,000 -26% 31 Dec 2021 20-F 01 May 2023 2022 FY
Q4 2020 ¥4,758,778,000 +¥3,621,305,000 +318% 31 Dec 2020 20-F 29 Apr 2022 2021 FY
Q3 2020 ¥2,960,017,000 30 Sep 2020 6-K 05 Feb 2021 2020 Q3
Q4 2019 ¥1,137,473,000 -¥450,805,000 -28% 31 Dec 2019 20-F 28 Apr 2021 2020 FY
Q4 2018 ¥1,588,278,000 31 Dec 2018 20-F 29 Apr 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.